Receptor protein found to be a key player in prostate cancer cells' drug resistance

NewsGuard 100/100 Score

Researchers have identified a receptor protein known as CHRM1 as a key player in prostate cancer cells' resistance to docetaxel, a commonly used chemotherapy drug to treat advanced cancer that has spread beyond the prostate. The discovery opens the door to new treatment strategies that could overcome this resistance. This could ultimately help extend the lives of those with prostate cancer, one of the leading causes of cancer deaths among men.

Led by a team of scientists at Washington State University, the study showed that blocking CHRM1 in resistant prostate cancer cell lines and an animal model based on patient-derived resistant tissue restored docetaxel's ability to kill cells and stop tumor growth. The researchers did this by using dicyclomine, a drug that selectively inhibits CHRM1 activity. Dicyclomine is already on the market as a generic drug and is currently used to treat symptoms of irritable bowel syndrome.

The effect was pretty dramatic in all the experimental models we tested. And because dicyclomine already has a clinical use, this work has immediate translational potential."

Boyang (Jason) Wu, associate professor in the WSU College of Pharmacy and Pharmaceutical Sciences and co-senior author on the study

Published in the journal Cell Reports Medicine, the researchers' findings support clinical testing to confirm whether combined use of docetaxel and dicyclomine could help overcome treatment resistance in prostate cancer patients. Docetaxel resistance can develop in prostate cancer after about six months of treatment. Chemotherapy drugs like docetaxel are among very few options available to patients with castration-resistant prostate cancer, a lethal form of the disease that no longer responds to hormone therapy.

Wu said this type of combination therapy could also potentially be used for other cancers that are currently being treated with docetaxel, such as breast and lung cancer. It may also be possible to use the same combination strategy with other similar chemotherapy drugs.

In addition to testing resistant cancer cell lines, the research team also tested cells that still responded to docetaxel treatment. They found that using dicyclomine to block CHRM1 in these cells made docetaxel more efficient at killing them. Wu said that this shows that prostate cancer patients could potentially benefit from a combination treatment strategy even before docetaxel resistance develops.

"What this suggests is that the lowest effective dose of docetaxel may be lower when the drug is combined with dicyclomine, compared to when docetaxel is used alone," Wu said. "Being able to use a lower dose could help reduce unwanted side effects and make treatment more manageable for patients."

Aside from Wu, co-authors on the study include co-senior author Tyler Bland-;a former WSU postdoctoral fellow who is now a clinical assistant professor at the University of Idaho-;as well as co-first authors Jing Wang, a recent WSU PhD graduate, and Jing Wei, a WSU postdoctoral fellow. The research team conducted the study in collaboration with scientists at the University of Washington, Medical University of Innsbruck in Austria and National Yang Ming Chiao Tung University in Taiwan.

Funding for this study came from a U.S. Department of Defense Prostate Cancer Research Program grant with additional support provided by the National Cancer Institute, a component of the National Institutes of Health, and WSU College of Pharmacy and Pharmaceutical Sciences startup funds.

Journal reference:

Wang, J., et al. (2024) Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer. Cell Reports Medicine.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
NCCN 2024 Annual Conference focuses on practical applications for improving cancer care